nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—KRAS—bile duct cancer	0.00281	0.00281	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—KRAS—bile duct cancer	0.00278	0.00278	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—HRAS—bile duct cancer	0.00277	0.00277	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TP53—bile duct cancer	0.00276	0.00276	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—NRAS—bile duct cancer	0.00264	0.00264	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—NRAS—bile duct cancer	0.00256	0.00256	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IDH1—bile duct cancer	0.00254	0.00254	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—bile duct cancer	0.00254	0.00254	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL6—bile duct cancer	0.00252	0.00252	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—bile duct cancer	0.0025	0.0025	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—NRAS—bile duct cancer	0.00247	0.00247	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—NRAS—bile duct cancer	0.00247	0.00247	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—bile duct cancer	0.00247	0.00247	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—bile duct cancer	0.00239	0.00239	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—TP53—bile duct cancer	0.00238	0.00238	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—bile duct cancer	0.00238	0.00238	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—HRAS—bile duct cancer	0.00236	0.00236	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—HRAS—bile duct cancer	0.00236	0.00236	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—ERBB2—bile duct cancer	0.00231	0.00231	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.00228	0.00228	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—KRAS—bile duct cancer	0.00227	0.00227	CbGpPWpGaD
Pimecrolimus—MTOR—CDC42 signaling events—HRAS—bile duct cancer	0.00225	0.00225	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.00223	0.00223	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—NRAS—bile duct cancer	0.00223	0.00223	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—bile duct cancer	0.00221	0.00221	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—KRAS—bile duct cancer	0.00221	0.00221	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—bile duct cancer	0.00219	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—KRAS—bile duct cancer	0.00219	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—ERBB2—bile duct cancer	0.00218	0.00218	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—EGFR—bile duct cancer	0.00214	0.00214	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—HRAS—bile duct cancer	0.00213	0.00213	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—KRAS—bile duct cancer	0.00213	0.00213	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—KRAS—bile duct cancer	0.00213	0.00213	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.00211	0.00211	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—EGFR—bile duct cancer	0.00209	0.00209	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—ERBB2—bile duct cancer	0.00208	0.00208	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—EGFR—bile duct cancer	0.00208	0.00208	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RNF43—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—NRAS—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—ERBB2—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—ERBB2—bile duct cancer	0.00206	0.00206	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—NRAS—bile duct cancer	0.00206	0.00206	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—ERBB2—bile duct cancer	0.00205	0.00205	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—EGFR—bile duct cancer	0.00203	0.00203	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bile duct cancer	0.00203	0.00203	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—bile duct cancer	0.00202	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—bile duct cancer	0.00202	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—MMP9—bile duct cancer	0.00198	0.00198	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—HRAS—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—ERBB2—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—ERBB2—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—KRAS—bile duct cancer	0.00192	0.00192	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—ERBB2—bile duct cancer	0.00191	0.00191	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—bile duct cancer	0.00189	0.00189	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—bile duct cancer	0.00189	0.00189	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—ERBB2—bile duct cancer	0.00188	0.00188	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.00188	0.00188	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—HRAS—bile duct cancer	0.00188	0.00188	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—bile duct cancer	0.00186	0.00186	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—bile duct cancer	0.00185	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—HRAS—bile duct cancer	0.00181	0.00181	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—HRAS—bile duct cancer	0.00181	0.00181	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—bile duct cancer	0.0018	0.0018	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—ERBB2—bile duct cancer	0.00178	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—KRAS—bile duct cancer	0.00178	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—bile duct cancer	0.00178	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—KRAS—bile duct cancer	0.00177	0.00177	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—NRAS—bile duct cancer	0.00176	0.00176	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—bile duct cancer	0.00173	0.00173	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—bile duct cancer	0.00173	0.00173	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—bile duct cancer	0.00171	0.00171	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—bile duct cancer	0.0017	0.0017	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—NRAS—bile duct cancer	0.00168	0.00168	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RNF43—bile duct cancer	0.00166	0.00166	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—NRAS—bile duct cancer	0.00166	0.00166	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—HRAS—bile duct cancer	0.00163	0.00163	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—bile duct cancer	0.00163	0.00163	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—bile duct cancer	0.0016	0.0016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—EGFR—bile duct cancer	0.0016	0.0016	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—NRAS—bile duct cancer	0.00158	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—NRAS—bile duct cancer	0.00157	0.00157	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—NRAS—bile duct cancer	0.00157	0.00157	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—bile duct cancer	0.00156	0.00156	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—NRAS—bile duct cancer	0.00156	0.00156	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—bile duct cancer	0.00154	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—bile duct cancer	0.00154	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—bile duct cancer	0.00153	0.00153	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—bile duct cancer	0.00152	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—HRAS—bile duct cancer	0.00151	0.00151	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—KRAS—bile duct cancer	0.00151	0.00151	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—EGFR—bile duct cancer	0.00151	0.00151	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—HRAS—bile duct cancer	0.0015	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—NRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—NRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—NRAS—bile duct cancer	0.00145	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—bile duct cancer	0.00145	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KRAS—bile duct cancer	0.00145	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—EGFR—bile duct cancer	0.00144	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—NRAS—bile duct cancer	0.00144	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—bile duct cancer	0.00144	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—EGFR—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—NRAS—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IDH1—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—EGFR—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—KRAS—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—EGFR—bile duct cancer	0.00142	0.00142	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bile duct cancer	0.0014	0.0014	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—KRAS—bile duct cancer	0.00136	0.00136	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—NRAS—bile duct cancer	0.00136	0.00136	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—KRAS—bile duct cancer	0.00135	0.00135	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—bile duct cancer	0.00135	0.00135	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFBR2—bile duct cancer	0.00135	0.00135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—KRAS—bile duct cancer	0.00135	0.00135	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—KRAS—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—EGFR—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—EGFR—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—EGFR—bile duct cancer	0.00132	0.00132	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—bile duct cancer	0.00132	0.00132	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—ERBB2—bile duct cancer	0.00131	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.00131	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—EGFR—bile duct cancer	0.00131	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.0013	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—HRAS—bile duct cancer	0.00129	0.00129	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SMAD4—bile duct cancer	0.00128	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—bile duct cancer	0.00127	0.00127	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—HRAS—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KRAS—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KRAS—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—KRAS—bile duct cancer	0.00125	0.00125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.00124	0.00124	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—EGFR—bile duct cancer	0.00124	0.00124	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—KRAS—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—HRAS—bile duct cancer	0.00121	0.00121	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.00118	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.00118	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—KRAS—bile duct cancer	0.00117	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RNF43—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—HRAS—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—HRAS—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	0.00115	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—HRAS—bile duct cancer	0.00115	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—HRAS—bile duct cancer	0.00115	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—HRAS—bile duct cancer	0.00114	0.00114	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.00112	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.00112	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—bile duct cancer	0.00111	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—bile duct cancer	0.0011	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—bile duct cancer	0.0011	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—bile duct cancer	0.00109	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—bile duct cancer	0.00106	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.00105	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—bile duct cancer	0.00105	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—bile duct cancer	0.00103	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.00103	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—bile duct cancer	0.00103	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—bile duct cancer	0.00102	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.00101	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—bile duct cancer	0.001	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NRAS—bile duct cancer	0.000999	0.000999	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—bile duct cancer	0.000992	0.000992	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS2—bile duct cancer	0.000952	0.000952	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.00095	0.00095	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFBR2—bile duct cancer	0.000946	0.000946	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GNAS—bile duct cancer	0.000913	0.000913	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—bile duct cancer	0.00091	0.00091	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000909	0.000909	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SMAD4—bile duct cancer	0.000896	0.000896	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KRAS—bile duct cancer	0.000859	0.000859	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—bile duct cancer	0.000814	0.000814	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFBR2—bile duct cancer	0.00076	0.00076	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FAR2—bile duct cancer	0.000756	0.000756	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HGF—bile duct cancer	0.000756	0.000756	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ERBB2—bile duct cancer	0.000749	0.000749	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—bile duct cancer	0.000745	0.000745	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—bile duct cancer	0.000731	0.000731	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SMAD4—bile duct cancer	0.000719	0.000719	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ERBB2—bile duct cancer	0.000719	0.000719	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERBB2—bile duct cancer	0.000716	0.000716	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—bile duct cancer	0.0007	0.0007	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—bile duct cancer	0.000699	0.000699	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—bile duct cancer	0.00057	0.00057	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—bile duct cancer	0.000547	0.000547	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—bile duct cancer	0.000545	0.000545	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS2—bile duct cancer	0.000535	0.000535	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFBR2—bile duct cancer	0.000532	0.000532	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—bile duct cancer	0.000519	0.000519	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GNAS—bile duct cancer	0.000513	0.000513	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—bile duct cancer	0.000506	0.000506	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMAD4—bile duct cancer	0.000504	0.000504	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—bile duct cancer	0.000501	0.000501	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—bile duct cancer	0.000498	0.000498	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—bile duct cancer	0.000496	0.000496	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—bile duct cancer	0.00049	0.00049	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—bile duct cancer	0.000471	0.000471	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—bile duct cancer	0.000469	0.000469	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—bile duct cancer	0.000436	0.000436	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—bile duct cancer	0.00043	0.00043	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—bile duct cancer	0.000417	0.000417	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—bile duct cancer	0.000403	0.000403	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—bile duct cancer	0.0004	0.0004	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—bile duct cancer	0.000399	0.000399	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—bile duct cancer	0.000398	0.000398	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—bile duct cancer	0.000394	0.000394	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—bile duct cancer	0.000381	0.000381	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—bile duct cancer	0.000381	0.000381	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—IDH2—bile duct cancer	0.000369	0.000369	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—bile duct cancer	0.000354	0.000354	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—bile duct cancer	0.000347	0.000347	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—bile duct cancer	0.000332	0.000332	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—bile duct cancer	0.000328	0.000328	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—IDH1—bile duct cancer	0.000318	0.000318	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—bile duct cancer	0.000306	0.000306	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—bile duct cancer	0.000302	0.000302	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—bile duct cancer	0.000292	0.000292	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—bile duct cancer	0.000286	0.000286	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—bile duct cancer	0.000285	0.000285	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—bile duct cancer	0.000282	0.000282	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—bile duct cancer	0.000279	0.000279	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—bile duct cancer	0.000279	0.000279	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—bile duct cancer	0.000267	0.000267	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—bile duct cancer	0.000264	0.000264	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—bile duct cancer	0.000243	0.000243	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—bile duct cancer	0.000242	0.000242	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—bile duct cancer	0.000232	0.000232	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—bile duct cancer	0.000224	0.000224	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—bile duct cancer	0.000214	0.000214	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—bile duct cancer	0.000214	0.000214	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC5A5—bile duct cancer	0.00021	0.00021	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—bile duct cancer	0.000199	0.000199	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—bile duct cancer	0.000195	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—bile duct cancer	0.000185	0.000185	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—bile duct cancer	0.000164	0.000164	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNAS—bile duct cancer	0.000163	0.000163	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—bile duct cancer	0.000157	0.000157	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—bile duct cancer	0.00015	0.00015	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—bile duct cancer	8.74e-05	8.74e-05	CbGpPWpGaD
